| P50 | author | Afshin Ostovar | Q54116625 |
| | Shokrollah Farrokhi | Q81439622 |
| | Azar Baradaran | Q86402996 |
| P2093 | author name string | Mohammad Reza Mohajeri | |
| | Mohammad Kazzem Gheybi | |
| | Parvaneh Hajalikhani | |
| P2860 | cites work | Adjuvant endocrine therapy for early breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline | Q27002430 |
| | HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity | Q27006811 |
| | Cancer statistics, 2013 | Q27860762 |
| | Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up | Q28306437 |
| | Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma | Q33421127 |
| | Breast cancer prognostic classification in the molecular era: the role of histological grade | Q34173440 |
| | HER2 signaling pathway and trastuzumab cardiotoxicity | Q34328064 |
| | Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials | Q34451337 |
| | Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study | Q35078787 |
| | A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections | Q36367606 |
| | HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. | Q36693285 |
| | Current approaches and future directions in the treatment of HER2-positive breast cancer | Q37330128 |
| | Current technologies for HER2 testing in breast cancer. | Q37832859 |
| | Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Q38053590 |
| | The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice | Q38175061 |
| | Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast | Q42523482 |
| | Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy | Q42616492 |
| | Progression and treatment of HER2-positive breast cancer | Q43189081 |
| | Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications. | Q43297978 |
| | A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer | Q45782977 |
| | Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. | Q46134374 |
| | Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations | Q46211466 |
| | Reliability of core needle biopsy for determining ER and HER2 status in breast cancer. | Q50891158 |
| | Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. | Q51510677 |
| | Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A | Q51912802 |
| | Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer. | Q54281256 |
| | Accuracy and Reproducibility of HER2 Status in Breast Cancer Using Immunohistochemistry: A Quality Control Study in Tuscany Evaluating the Impact of Updated 2013 ASCO/CAP Recommendations. | Q54311896 |
| | Analysis of HER2 status in breast carcinoma by fully automated HER2 fluorescence in situ hybridization (FISH): comparison of two immunohistochemical tests and manual FISH. | Q54387877 |
| | Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. | Q54581383 |
| | Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update | Q57130157 |
| P433 | issue | 5 | |
| P921 | main subject | immunohistochemistry | Q899285 |
| P304 | page(s) | 365-371 | |
| P577 | publication date | 2016-01-27 | |
| P1433 | published in | Acta Pathologica et Microbiologica Scandinavica | Q15756643 |
| P1476 | title | Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients | |
| P478 | volume | 124 | |